Understanding the role biologics can play in healthcare.

Biologics & Biosimilars

Jim Sliney Jr, Editor

Director of Patient Outreach, Patients Rising

Why we’re talking about Biologics

This module was designed to help patients and their allies understand the role biologics can play in healthcare. When we approached our community about this topic, they informed us of gaps in knowledge that needed attention. We began digging, and what we found is what you see here.

We have curated information from only the most reliable sources on the subject. We pulled together information from doctors, scientists, industry and patients to understand what biologics and biosimilars are, what makes them different from other drugs, and the role they can play in your health.

Our hope is that this information leads to productive conversations with your healthcare team and opens doors to new avenues of treatment you can access.


Biosimilars are biologic medicines that are highly similar to the original biologic medicine,sometimes we refer to this as the “name brand”. For the purposes of this e-book we will refer to them as originator biologics. 

Our hope is to provide enough information for you to make informed, educated decisions about the use of biologic drugs in your treatment plan..


Surabhi Dangi-Garimella, Ph.D.
SDG AdvoHealth, LLC

Jim Sliney Jr.
Director of Patient Outreach
Patients Rising University

More on Biologics

Biologics Infographic

Attitudes around cost, safety and efficacy

Biologics Survey

Patients Rising University conducted a survey to better understand patient experiences and attitudes regarding biologics and biosimilars. We wanted to know just how aware patients are about these treatments, what makes them different in the patient perspective and what their general attitudes are on related issues.


Price: one the of largest barriers to medical treatment and accessible medicine. As many patients struggle to afford the high price tags at the pharmacy, there might soon be a solution. As more biosimilars enter the commercial market, some experts are claiming that they will actually lead to lower drug costs for patients everywhere. 

In the second episode of the Patients Rising Podcast, we look into the relationship between biosimilars and drug prices, break down what exactly biosimilars are, and how they are changing the healthcare landscape. 


Chad Pettit, Executive Director, Global Value Access and Policy, Amgen Biosimilars Business Unit, Thousand Oaks, California.

Chad Pettit has worked with biotechnology company Amgen for nearly 20 years. In his current role as Executive Director, Mr. Pettit serves as a liaison with biopharmaceutical companies on biosimilar policy. He also focuses on introducing biosimilars to the market and working with policy to ensure commercialization leads to cost savings in all global regions. He works at the intersection of policy and biopharmaceutical medicine to facilitate greater accessibility and has an acute understanding of the impacts biosimilars have on the global health care market. Most recently, he has worked to construct a global market access launch strategy for Amgen’s 10 biosimilars. 

Previously at Amgen, Mr. Pettit served on the U.S. Biosimilars industry trade group as the Amgen Board Member. 

Mr. Pettit earned a B.S. in Chemical Engineering from the University of California, Davis, and an M.B.A. from the University of California, Los Angeles. 


Terry Wilcox, Executive Director, Patients Rising

Dr. Robert Goldberg, “Dr. Bob”, Co-Founder and Vice President of the Center for Medicine in the Public Interest.

Kate Pecora, Field Correspondent 


Public Workshop: FDA/FTC Workshop on a Competitive Marketplace for Biosimilars

Heimerdinger Foundation

Ceres Community Project

Patient’s Rising Concierge


Articles & Insights

You'll receive updates about new resources, patient stories and insights, advocacy work, and alerts about patient-support events.
The latest about patient advocacy

Join our Email List

Get notified about new stories and resources to empower patients and caregivers.